View in EDS

Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.

Saved in:
Bibliographic Details
Title: Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Authors: Pollom, Erqi L.1, Fujimoto, Dylann1, Wynne, Jacob1, Seiger, Kira1, Modlin, Leslie A.1, Jacobs, Lisa R.1, Azoulay, Melissa1,2, von Eyben, Rie1, Tupper, Laurie1, Gibbs, Iris C.1, Hancock, Steven L.1, Li, Gordon3, Chang, Steven D.3, Adler, John R.3, Harsh, Griffith R.3, Harraher, Ciara3, Nagpal, Seema3,4, Thomas, Reena P.3,4, Recht, Lawrence D.3,4, Choi, Clara Y.H.1,5
Source: International Journal of Radiation Oncology, Biology, Physics. May2017, Vol. 98 Issue 1, p123-130. 8p.
Subjects: Glioblastoma multiforme, Glioblastoma multiforme treatment, Stereotactic radiosurgery, Adjuvant treatment of cancer, Temozolomide, Quality of life, Diagnosis, Therapeutics, Antineoplastic agents, Brain tumors, Cancer relapse, Clinical trials, Combined modality therapy, Communication, Comparative studies, Gliomas, Longitudinal method, Research methodology, Medical cooperation, Questionnaires, Radiosurgery, Research, Research funding, Evaluation research, Treatment effectiveness, Disease progression, Kaplan-Meier estimator, Dacarbazine
Abstract: Purpose: We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide.Methods: HRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 (QLQ-C30) general, the EORTC quality of life questionnaire-brain cancer specific module (QLQ-BN20), and the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT). Questionnaires were completed at baseline and at every follow-up visit after completion of radiosurgery. Changes from baseline for 9 predefined HRQOL measures (global quality of life, physical functioning, social functioning, emotional functioning, motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty) were calculated at every time point.Results: With a median follow-up time of 10.4 months (range, 0.4-52 months), 139 total HRQOL questionnaires were completed by the 30 patients on trial. Compliance with HRQOL assessment was 76% at 12 months. Communication deficit significantly worsened over time, with a decline of 1.7 points per month (P=.008). No significant changes over time were detected in the other 8 scales of our primary analysis, including global quality of life. Although 8 patients (27%) experienced adverse radiation effects (ARE) on this dose escalation trial, it was not associated with a statistically significant decline in any of the primary HRQOL scales. Disease progression was associated with communication deficit, with patients experiencing an average worsening of 13.9 points per month after progression compared with 0.7 points per month before progression (P=.01).Conclusion: On this 5-fraction dose escalation protocol for newly diagnosed GBM, overall HRQOL remained stable and appears similar to historical controls of 30 fractions of radiation therapy. Tumor recurrence was associated with worsening communication deficit, and ARE did not correlate with a decline in HRQOL. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Be the first to leave a comment!
You must be logged in first